CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:The Role of NK Cells in Cancer Immunotherapy: Mechanisms, Evasion Strategies, and Therapeutic Advances.
The Role of NK Cells in Cancer Immunotherapy: Mechanisms, Evasion Strategies, and Therapeutic Advances.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
全面回顾NK细胞生物学、肿瘤免疫逃逸及免疫治疗应用领域近十年的同行评审研究,重点分析评估NK细胞扩增策略、细胞因子刺激和CAR-NK细胞疗法进展的临床前模型及临床试验数据。
NK细胞通过释放细胞毒性颗粒、死亡受体通路和分泌细胞因子清除肿瘤。但肿瘤细胞可下调活化配体、分泌免疫抑制分子并改变肿瘤微环境,以逃避NK细胞介导的免疫。CAR-NK及与免疫检查点抑制剂联合等新疗法可增强NK细胞持续存在,并提高其对血液系统恶性肿瘤和实体瘤的疗效。临床试验显示,与CAR-T 疗法相比,这些疗法安全性更佳,细胞因子释放综合征及移植物抗宿主病发生率较低。
NK细胞免疫疗法前景广阔,但仍面临持续性有限和肿瘤诱导免疫抑制等挑战。解决这些问题对于优化NK细胞疗法、推进适用范围更广的新一代现货型免疫疗法至关重要。
Background/Objectives: Natural killer (NK) cells play a crucial role in tumor surveillance by exerting cytotoxic activity and modulating immune responses.
However, tumors employ diverse evasion strategies that limit NK cell effectiveness. This review aims to explore the molecular mechanisms of NK cell activation and inhibition in cancer, the influence of the tumor microenvironment, and the latest advancements in NK cell-based immunotherapies, including adoptive NK cell transfer and Chimeric Antigen Receptor-Natural Killer (CAR-NK) cell therapies.
Methods: A comprehensive literature review was conducted, prioritizing peer-reviewed studies from the last decade on NK cell biology, tumor immune evasion, and immunotherapeutic applications. The analysis includes data from preclinical models and clinical trials evaluating NK cell expansion strategies, cytokine-based stimulation, and CAR-NK cell therapy developments. Results: NK cells eliminate tumors through cytotoxic granule release, death receptor pathways, and cytokine secretion.
However, tumor cells evade NK-mediated immunity by downregulating activating ligands, secreting immunosuppressive molecules, and altering the tumor microenvironment. Novel NK cell-based therapies, such as CAR-NK cells and combination approaches with immune checkpoint inhibitors, enhance NK cell persistence and therapeutic efficacy against both hematologic and solid malignancies.
Clinical trials suggest improved safety profiles compared to CAR-T therapies, with reduced cytokine release syndrome and graft-versus-host disease. Conclusions: While NK cell-based immunotherapies hold great promise, challenges remain, including limited persistence and tumor-induced immunosuppression. Addressing these hurdles will be critical for optimizing NK cell therapies and advancing next-generation, off-the-shelf immunotherapeutics for broader clinical applications.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。